Every Form 4 that CareDx, Inc. (CDNA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CDNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDNA filings page.
CareDx, Inc. reported that 997 shares of common stock were withheld from Secretary and General Counsel Jeffrey Adam Novack on October 1, 2026, to satisfy tax-withholding obligations connected with the issuance of shares upon vesting of restricted stock units. The reported price was $66.23 per share, and his direct holdings afterward were 105,078 shares.
CareDx, Inc. (CDNA) President and CEO John Walter Hanna Jr. had 8,511 shares withheld on October 1, 2026, to satisfy tax withholding obligations connected with the vesting of restricted stock units. He directly held 644,937 shares after the transaction.
CareDx, Inc. CFO & COO Keith Kennedy had 3,018 shares of common stock withheld by the issuer on October 1, 2026, to satisfy tax-withholding obligations connected with issuing shares upon vesting of restricted stock units. The reported price was $66.23 per share; his direct holdings after the transaction were 208,686 shares.
CareDx, Inc. Chief Commercial Officer Jessica Meng had 2,619 common shares withheld by the issuer on October 1, 2026, to satisfy tax withholding obligations tied to shares issued upon vesting of restricted stock units. The reported price was $66.23 per share; her direct holdings after the transaction were 158,980 shares.
CareDx, Inc. director Michael Goldberg acquired 588 shares of common stock on October 2, 2026, as an automatic quarterly grant in lieu of cash for non-employee director compensation under the issuer’s Outside Director Compensation Policy. After the grant, Goldberg directly held 62,326 shares. The Cavallo Trust held 91,045 shares; Goldberg and his spouse are trustees.
CareDx, Inc. (CDNA) reported that its CFO & COO, Keith Kennedy, had 8,220 shares of common stock withheld on September 12, 2026 to pay tax liabilities related to the vesting of restricted stock units. These shares were withheld by the company and not sold in the market. Following this tax-withholding transaction, Kennedy directly holds 211,704 shares of CareDx common stock.
CareDx, Inc. reported that Chief Commercial Officer Jessica Meng had 6,688 shares of common stock withheld on September 12, 2026 to satisfy tax withholding obligations related to vesting of restricted stock units. The shares were valued at $52.37 per share, leaving her with 161,599 shares held directly.
The transaction was a tax-withholding disposition effected by the issuer and not an open-market sale, and no Rule 10b5-1 trading plan is reported for this filing.
CareDx, Inc. director George Bickerstaff sold 20,000 shares of Common Stock on August 5, 2026 in a non-derivative sale transaction. The shares were sold at a weighted average price of $46.285 per share, across trades from $46.14 to $47.06, leaving him directly holding 134,061 shares.
CareDx, Inc. director Christine Cournoyer sold 16,000 shares of common stock on 2026-08-04 in open-market transactions under a Rule 10b5-1 trading plan. The weighted average sale price was $46.9358 per share, within a $46.25–$47.2250 range, leaving her with 42,943 shares held directly.
CareDx, Inc. reports that Secretary and General Counsel Jeffrey Adam Novack sold a total of 2,688 shares of common stock on August 5, 2026, in open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. The sales comprised 2,188 shares at a weighted average price of $46.1492 (range $45.49–$46.45) and 500 shares at $46.75 (range $46.59–$46.94).
CareDx, Inc. director Michael Goldberg reported selling 44,700 shares of Common Stock on August 4, 2026 at an average price of $47.0581 per share. After the sale he holds 61,738 shares directly and 91,045 shares indirectly through the Cavallo Trust, where he and his spouse are trustees.
CareDx, Inc. reported that Secretary and General Counsel Jeffrey Adam Novack had 2,872 shares of common stock withheld on August 1, 2026 at $47.85 per share to satisfy tax withholding obligations related to vesting restricted stock units. After this disposition, he directly holds 108,763 shares of CareDx common stock.
CareDx, Inc. director and President & CEO Hanna John Walter JR reported option exercises and share sales dated July 16, 2026. He exercised 118,000 employee stock options at $8.2000 per share, acquiring common stock, and sold 118,000 shares in sales at weighted average prices of $36.1141 and $39.0137, effected pursuant to a Rule 10b5-1 trading plan adopted December 12, 2025. Following these transactions, he reported direct ownership of 653,448 common shares and 512,706 employee stock options.
CareDx, Inc. director Hannah Valantine reported multiple equity transactions in Common Stock on July 16, 2026. She sold a total of 28,779 shares, including 28,679 shares at a weighted average price of $36.1445 (individual trades from $35.55 to $36.50) and 100 shares at $36.55, under a Rule 10b5-1 trading plan adopted on December 11, 2025. She also exercised fully vested stock options for 28,779 shares at exercise prices of $7.96, $14.19 and $20.56 per share. Following the reported transactions, she held 36,786 shares of CareDx Common Stock directly.
Goldberg Michael reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Michael Goldberg reported an automatic equity grant and updated holdings. He received a grant of 1,746 shares of Common Stock at $0.00 per share as quarterly non-employee director compensation in lieu of cash under the company’s Outside Director Compensation Policy.
Following this grant, Goldberg holds 106,438 Common Stock shares directly. A separate entry shows 91,045 Common Stock shares held indirectly by the Cavallo Trust, for which Goldberg and his spouse serve as trustees. The filing reflects routine compensation and ownership reporting rather than open-market buying or selling.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported a routine tax-withholding share disposition. On the vesting of restricted stock units, 8,511 shares of common stock were withheld by the company at an implied value of $29.25 per share to cover tax obligations. After this withholding, he directly holds 653,448 shares of CareDx common stock.
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack reported a routine tax-related share disposition. On this Form 4, 997 shares of common stock were withheld by the company to cover tax obligations tied to the vesting of restricted stock units, at a value of $29.25 per share. After this withholding, Novack directly holds 111,635 shares of CareDx common stock.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported a Form 4 showing a tax-related share disposition rather than an open-market trade. On this date, 2,411 shares of common stock were withheld by the company at $29.25 per share to cover tax obligations tied to vesting restricted stock units. After this withholding, she directly owned 168,287 shares, which include 1,306 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2026.
CareDx, Inc. executive Keith Kennedy, the CFO and COO, reported a routine tax-related share disposition linked to equity compensation. The company withheld 2,930 shares of common stock at $29.25 per share to cover tax obligations arising from the vesting of restricted stock units, rather than an open-market sale. After this withholding, Kennedy directly holds 219,924 shares of CareDx common stock. His holdings also include 1,306 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2026, reflecting ongoing participation in employee ownership programs.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported a combination of option exercises and share sales in June. He exercised employee stock options to acquire 70,000 shares of common stock at an exercise price of $8.20 per share across several transactions.
On June 26 and June 29, 2026, he sold a total of 40,000 shares of common stock in open-market transactions at a weighted average price of $29.244 per share, with individual prices ranging from $29.00 to $29.58. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating they were scheduled in advance.
Following these transactions, Hanna directly holds 661,959 shares of CareDx common stock. The underlying options relate to an award vesting over four years, with one-quarter vesting on April 15, 2025 and the remainder vesting monthly thereafter, and expiring on April 14, 2034.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported an open-market sale of 17,683 shares of Common Stock on June 15, 2026 at a weighted average price of $24.0274 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 13, 2024.
After this transaction, he continues to directly hold 631,959 shares of CareDx common stock, according to the filing.
CareDx, Inc. director Hannah Valantine reported both an equity grant and a share sale. On June 12, 2026, she acquired 9,795 shares of Common Stock as a grant with no cash paid, represented by restricted stock units that vest 100% on the earlier of the one-year anniversary of grant or immediately before the first Annual Meeting after the grant date, subject to continuous service. On June 15, 2026, she sold 12,103 shares of Common Stock in an open-market transaction at a weighted average price of $23.1123 per share, with individual sale prices ranging from $23.00 to $23.30. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, and she held 36,686 shares directly after the sale.
COURNOYER CHRISTINE reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Christine Cournoyer received a grant of 9,795 shares of common stock in the form of restricted stock units. The RSUs vest 100% on the earlier of one year after the grant date or immediately before the first annual meeting after the grant, subject to continued service. Following this grant, she directly holds 58,943 shares.
CareDx, Inc. reported that director Richard Bryan Riggsbee acquired 9,795 shares of common stock through a grant of restricted stock units. These RSUs were awarded at no cash cost per share and are a form of equity compensation, not an open-market purchase.
According to the filing, all of the RSUs vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the first Annual Meeting that occurs after the grant date, subject to his continuous service. Following this award, Riggsbee directly holds 39,312 shares of CareDx common stock.
Cohen Fred E reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Fred E. Cohen received an equity grant of 9,795 shares of Common Stock in the form of restricted stock units. These RSUs vest 100% on the earlier of one year from the grant date or the day before the first Annual Meeting after the grant date, subject to his continuous service. Following this award, he holds 165,060 shares directly.
Gunasekaran Suresh reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Suresh Gunasekaran reported receiving an equity award of 9,795 shares of Common Stock, represented by restricted stock units (RSUs). These RSUs vest 100% on the earlier of one year after the grant or the day immediately before the first Annual Meeting after the grant, subject to his continuous service. Following this award, he holds 37,248 shares directly.
Bickerstaff George reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director George Bickerstaff received an equity award in the form of 9,795 shares of Common Stock represented by restricted stock units. These RSUs were granted at no cash cost to him and are part of his compensation.
The RSUs vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the first Annual Meeting that occurs after the grant date, subject to his continuous service through that time. Following this award, he holds 154,061 shares of Common Stock directly.
Goldberg Michael reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Michael Goldberg reported receiving a grant of 9,795 restricted stock units (RSUs) of common stock at no cash cost, as a compensation award rather than an open‑market purchase.
The RSUs vest 100% on the earlier of the one‑year anniversary of the grant or the day immediately before the first Annual Meeting after the grant, subject to his continuous service. Following this award, he directly holds 195,737 shares of common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported an open-market sale of 21,998 shares of Common Stock on June 11, 2026 at a weighted average price of $24.0223 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 13, 2024, and left him with 649,642 shares held directly.
CareDx, Inc. reported that Secretary and General Counsel Jeffrey Adam Novack had 1,292 shares of common stock withheld by the company at $21.95 per share to cover tax obligations tied to the vesting of restricted stock units. After this tax-withholding disposition, he directly holds 112,632 shares of CareDx common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr. sold 4,835 shares of Common Stock in an open-market transaction at a weighted average price between $24.00 and $24.02 per share on June 4, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 13, 2024. Following the sale, he continues to hold 671,640 shares directly, indicating the transaction represents only a small portion of his overall position.
CareDx, Inc. director Arthur A. Torres reported selling a total of 10,570 shares of common stock in open-market transactions over two days. He sold 4,086 shares on May 14, 2026 at a weighted average price of $20.9735 per share, in trades ranging from $20.96 to $21.03. He then sold 6,484 shares on May 15, 2026 at a weighted average price of $19.8917 per share, in trades ranging from $19.73 to $20.105. After these sales, Torres directly holds 38,665 shares of CareDx common stock.
CareDx, Inc. reported that its Secretary and General Counsel, Jeffrey Adam Novack, executed an open-market sale of 2,688 shares of common stock on May 5, 2026 at a weighted average price of 20.6775 per share. After the sale, he directly owned 113,924 shares of CareDx common stock. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan, which had been adopted on September 4, 2025, and the sale prices ranged from 20.405 to 21.26 per share.
CareDx, Inc. reported a routine insider tax-related transaction by its Secretary and General Counsel, Jeffrey Adam Novack. On May 1, 2026, 2,873 shares of common stock were withheld by the company at $21.50 per share to cover tax obligations arising from the vesting of restricted stock units. After this withholding, Novack directly held 116,612 shares of CareDx common stock. This was a compensation-related tax-withholding event, not an open-market purchase or sale.
Kennedy Keith reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. CFO & COO Keith Kennedy received a grant of 24,134 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share. After this award, he directly holds 221,548 shares.
According to the terms, one-third of these RSUs will vest on April 6, 2027. The remaining two-thirds will vest in equal quarterly installments over the next eight quarters, so that all units vest by the third anniversary of April 6, 2027, if his employment continues through each vesting date.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported an open-market sale of Common Stock. On April 16, he sold 10,282 shares at $21.12 per share in a single transaction. The filing states the sale was made under a Rule 10b5-1 trading plan adopted on December 13, 2024, and he continues to own 676,475 shares directly after the transaction.
CareDx, Inc.'s President and CEO John Walter Hanna Jr. reported a routine tax-related share disposition. On the vesting of restricted stock units, 62,049 shares of common stock were withheld by the company at $17.57 per share to cover tax obligations. After this withholding, he continues to hold 686,757 common shares directly, indicating he retains a substantial equity position in the company.
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack reported a routine tax-related share disposition. On the vesting of restricted stock units, 1,892 shares of common stock were withheld by the company at an implied value of $17.82 per share to cover tax obligations.
After this withholding, Novack directly holds 119,485 shares of CareDx common stock, indicating he retains a substantial equity stake even after satisfying these tax liabilities.
CareDx, Inc. President and CEO Hanna John Walter JR reported a routine tax-related share withholding. On issuance of shares upon vesting of restricted stock units, 35,037 shares of common stock were withheld at $17.87 per share to satisfy tax withholding obligations. After this non‑market transaction, he directly holds 748,806 shares of CareDx common stock.
CareDx, Inc. executive Keith Kennedy, the company’s CFO and COO, reported a routine tax-related share withholding. On the vesting of restricted stock units, 11,725 shares of common stock were withheld by the issuer at $17.87 per share to cover tax obligations.
Following this tax-withholding disposition, Kennedy directly holds 197,414 shares of CareDx common stock. The transaction reflects compensation-related share settlement mechanics rather than an open-market purchase or sale.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported a tax-related share disposition tied to vested restricted stock units. On the vesting of these RSUs, 7,386 shares of Common Stock were withheld by CareDx at $17.87 per share to cover tax withholding obligations.
After this non-market, tax-withholding transaction, Meng directly holds 169,392 shares of CareDx common stock. The event reflects routine share withholding for taxes rather than an open-market sale or purchase decision.
CareDx, Inc. reported that Secretary and General Counsel Jeffrey Adam Novack had 3,987 shares of common stock withheld on April 1, 2026 to cover tax obligations tied to the vesting of restricted stock units. These shares were retained by the company rather than sold in the market. After this tax-withholding transaction, he directly holds 121,377 shares of CareDx common stock.
Goldberg Michael reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Michael Goldberg received an automatic quarterly grant of 1,981 shares of common stock on 2026-04-02. The shares were granted at no cash cost in lieu of cash non-employee director compensation under the company’s Outside Director Compensation Policy. Following this award, he directly holds 185,942 common shares.
CareDx, Inc. director Michael Goldberg exercised stock options to acquire additional common shares. On March 31, 2026, he exercised options covering 26,500 shares of CareDx common stock at exercise prices of $5.02, $4.95, and $1.22 per share.
Following these option exercises, Goldberg directly owned 183,961 shares of CareDx common stock. The exercised options were originally subject to vesting schedules beginning in 2016 and 2017, with monthly vesting thereafter as described in the filing footnotes. No sales or gifts were reported in this filing.
CareDx Chief Operating Officer Kennedy Keith reported equity compensation and related tax withholding transactions in company common stock. On February 2, 2026, Keith received 60,000 shares represented by restricted stock units at $0 per share, which will vest over three years starting April 6, 2027. Keith also acquired 14,474 shares from performance-based restricted stock units that were earned after performance goals were certified on February 2, 2026. To cover tax obligations from the PRSU vesting, 4,644 shares were withheld at a price of $20.42 per share. After these transactions, Keith directly owns 209,139 CareDx common shares.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported equity awards and a related tax withholding transaction. On February 2, 2026, she was granted 60,000 restricted stock units (RSUs), which vest one-third on April 6, 2027 and the remaining two-thirds in eight equal quarterly installments so that all RSUs vest by the third anniversary of April 6, 2027, subject to continuous employment. She also earned 11,579 shares from a performance restricted stock unit (PRSU) award initially granted on February 1, 2025, after performance criteria were certified on February 2, 2026. In connection with the PRSU vesting, 4,430 shares of common stock were withheld at $20.42 per share to satisfy tax withholding obligations, leaving her with 176,778 directly held common shares.
CareDx, Inc. Chief Financial Officer Nathan Smith reported equity compensation and related tax withholding transactions. On February 2, 2026 he was granted 33,000 restricted stock units, which will vest in stages beginning April 6, 2027 and fully vest three years after that date, subject to continued employment.
He also acquired 7,875 common shares at no cost from a performance RSU award that was originally granted on February 1, 2025 and earned after performance goals were certified on February 2, 2026. To cover tax withholding on the PRSU vesting, 3,859 shares were withheld at a price of $20.42 per share, leaving him with 79,016 directly owned shares.
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack reported multiple equity transactions in company common stock. He was granted 33,000 restricted stock units that begin vesting on April 6, 2027 over three years, subject to continued employment, and 4,342 shares from a performance RSU award earned after performance criteria were certified on February 2, 2026. To cover tax withholding on PRSU and RSU vesting, 2,492 and 2,970 shares, respectively, were withheld by CareDx. On February 3, 2026, 4,441 shares were sold at $20.5553 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Novack directly held 125,364 shares of CareDx common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported equity compensation and related tax withholding transactions. On February 2, 2026, he was granted 162,500 restricted stock units (RSUs) at $0 per share. One-third of these RSUs will vest on April 6, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following eight quarters, so that all RSUs vest by the third anniversary of April 6, 2027, subject to continued employment.
He also acquired 37,632 shares of common stock at $0 per share, earned from a performance restricted stock unit (PRSU) award initially granted on February 1, 2025, after performance criteria were certified on February 2, 2026. To cover tax withholding on the PRSU vesting, 13,694 shares were withheld at a price of $20.42 per share. After these transactions, he directly owned 783,843 shares of CareDx common stock.
CareDx, Inc. President and CEO John Walter Hanna Jr., who is also a director, reported open-market sales of the company’s common stock. On January 21, 2026, he sold 200 shares at $21.00 per share, and on January 22, 2026, he sold 19,280 shares at a weighted average price of $21.163 per share. These transactions were coded as open market sales and were made under a Rule 10b5-1 trading plan adopted on December 13, 2024. Following the later transaction, he beneficially owned 597,405 shares of CareDx common stock directly.